Cart
sales@molnova.com
BPR1J-097 hydrochloride
CAS No. ——
BPR1J-097 hydrochloride ( —— )
Catalog No. M17703 CAS No. ——
BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 94 | Get Quote |
|
| 10MG | 154 | Get Quote |
|
| 50MG | 473 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBPR1J-097 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionBPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
-
DescriptionBPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorFLT3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight553.07
-
Molecular FormulaC27H29ClN6O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)C4=CC(=CC=C4)NS(=O)(=O)C5=CC=CC=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lin WH, et al. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br J Cancer. 2012 Jan 31;106(3):475-81.
molnova catalog
related products
-
PIK-90
PIK-90 is a potent DNA-PK and PI3K inhibitor that inhibits p110α, p110γ and DNA-PK with IC50s of 11, 18 and 13 nM, respectively.
-
PQR309
PQR309 (Bimiralisib) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50 of 33, 451, 661, 708 and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively.
-
ZSTK-474
A potent inhibitor of class I PI3K isoforms with IC50 of 17 nM, 53 nM, and 6 nM for p110β, p110γ, and p110δ, respectively.
